Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference

March 2, 2020

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the cancellation of its planned March 3 presentation and webcast at the Cowen Health Care Conference. Following implementation of a companywide travel and meetings policy that is designed to reduce potential disruption from coronavirus, the Vertex senior management team will, as a precautionary measure, no longer attend the conference.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney disease. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)

View source version on businesswire.com: https://www.businesswire.com/news/home/20200302005943/en/

Investors:
Michael Partridge, 617-341-6108
Zach Barber, 617-341-6470
Leah Gibson, 617-961-1507

Source: Vertex Pharmaceuticals Incorporated